Target intelligence / Profile preview

Proton-coupled amino acid transporter (PAT) (PAT)

Target
PAT
Molecular classification
Transporter, Solute carrier
01

Overview

Proton-coupled amino acid transporters (PATs), belonging to the SLC36 family, are membrane proteins that facilitate the movement of small neutral amino acids and their derivatives across cellular and organelle membranes. These transporters, primarily PAT1 (SLC36A1) and PAT2 (SLC36A2), function as secondary active symporters that couple the transport of substrates like glycine, alanine, and proline to the movement of protons down their electrochemical gradient (Thwaites & Anderson, 2011). PAT1 is notably expressed in the apical membrane of the small intestine for nutrient absorption and in lysosomes for amino acid efflux, while PAT2 is essential for renal reabsorption in the proximal tubule (UniProt, 2024). Beyond their transport function, PATs act as "transceptors" that sense amino acid availability to activate the mTORC1 signaling pathway, thereby regulating cell growth and proliferation (Fan & Goberdhan, 2018). This signaling role links PATs to various cancers, where their overexpression supports tumor growth and survival. PATs also play a significant role in pharmacology by mediating the intestinal absorption and renal disposition of amino acid-mimetic drugs, such as the anti-epileptic vigabatrin and the investigational sleep aid gaboxadol (NIH, 2011).

Other names
Solute carrier family 36SLC36 familyProton-assisted amino acid transporterLysosomal amino acid transporterLYAATTramdorin
02

Mechanism of action

Proton-coupled symport of small neutral amino acids and amino acid-mimetic drugs (PAT1 and PAT2) or facilitated diffusion (PAT4) across the plasma or lysosomal membranes (Thwaites & Anderson, 2011; Fan & Goberdhan, 2018).

03

Biological functions

Amino acid transportNutrient sensingmTORC1 activationpH regulationIntestinal absorptionRenal reabsorptionLysosomal efflux
04

Disease associations

CancerMetabolic disorderIminoglycinuriaHyperglycinuriaObesity
05

Safety considerations

Potential for drug-drug interactions (DDIs) in the intestine and kidneyInterference with mTORC1-mediated nutrient sensingMetabolic disturbances from essential amino acid transport inhibition
06

Interacting drugs

Vigabatrin

8 more in the full profile.

07

Biomarkers

SLC36A1 mRNA/protein expressionSLC36A4 mRNA/protein expressionUrinary glycine levelsUrinary proline levels

Beyond the preview

Go deeper on Proton-coupled amino acid transporter (PAT) (PAT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proton-coupled amino acid transporter (PAT) (PAT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call